Nanobac Pharmaceuticals(OTC) NNBP

Market Cap$200.00

Since IPO (2003)-100%

5 Year-100%

1 Year+0%

1 Month-99%

$0.00

+0.00%

+0.00Today

Nanobac Pharmaceuticals last closing stock price
Metric	Price	Date
Last close	USD 0.00	2026-09-01

Nanobac Pharmaceuticals stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0%	USD 0.00	2026-08-24
1 month	-99%	USD 0.00	2026-07-21
3 month	+0%	USD 0.00	2026-06-03
Year to date	+0%	USD 0.00	2025-12-31
1 year	+0%	USD 0.00	2025-08-15
3 year	+0%	USD 0.00	2023-08-25
5 year	-99.83%	USD 0.00	2021-09-02
Since inception	-100%	USD 0.50	2003-06-16

Nanobac Pharmaceuticals Financials at a Glance

Market Cap

$200.00

Revenue (TTM)

$17.62K

Net Income (TTM)

-$6.58M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

5.05 (High)

Dividend

$0.00

Beta (Volatility)

5.05 (High)

Price

$0.00

Volume

2,200

Open

$0.00

Price

$0.00

Volume

2,200

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

Dividend

$0.00

Beta (Volatility)

5.05 (High)

Price

$0.00

Volume

2,200

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

NNBP News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Nanobac Pharmaceuticals

Nanobac Pharmaceuticals, Incorporated is focused on enhancing human health through innovative products aimed at identifying and managing calcifying nanoparticles (CNPs). The company specializes in in vitro diagnostic (IVD) kits, including assays and reagents for CNP detection, and conducts research on various urological and cardiovascular diseases.

Products and Services

In vitro diagnostic (IVD) kits for CNP detection
NANO-CAPTURE and NANO-SERO diagnostic assays
Research on urological diseases and cardiovascular conditions

Growth Outlook

Continued focus on expanding diagnostic product offerings
Research initiatives targeting chronic prostatitis and kidney stones
Potential market growth in cardiovascular disease diagnostics

Financial Highlights

Recent quarterly revenue of 4,368, indicating product demand
Trailing twelve months (TTM) gross profit margin of 17.6%
Operating income margin of 278.9% reflects operational efficiency

Nanobac Pharmaceuticals, Incorporated is positioned in the biotechnology sector, with a commitment to developing diagnostic solutions for critical health issues. The company's innovative approach to CNPs and its ongoing research into urological and cardiovascular diseases highlight its potential for growth. Recent financial data indicates a steady revenue stream and operational efficiency, suggesting a promising outlook for future developments. Investors may find interest in the company's unique market position and its focus on addressing significant health challenges.

AI Generated • Aug 29, 2026

Industry

Biotechnology

Sector

Health Care

Headquarters

Tampa, FL 33607, US

NNBP Financials

Key Financial Metrics (TTM)

Gross Margin

17.60%

Operating Margin

27891.78%

Net Income Margin

-37319.74%

Return on Equity

357.99%

Return on Capital

279.30%

Return on Assets

-91.08%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$200.00

Shares Outstanding

249.51M

Volume

2.20K

Avg. Volume

3.01K

Financials (TTM)

Gross Profit

$3.10K

Operating Income

$4.92M

EBITDA

-$3.10M

Operating Cash Flow

-$910.89K

Capital Expenditure

-$1.53K

Free Cash Flow

-$912.42K

Cash & ST Invst.

$3.93K

Total Debt

$4.12M

Nanobac Pharmaceuticals Performance Analysis

Nanobac Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q1	2007-03-31	114.1%
Q2	2007-06-30	-51.5%
Q3	2007-09-30	138.9%
Q4	2007-12-31	-24.8%

Nanobac Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q1	2007-03-31	-74.0%
Q2	2007-06-30	82.4%
Q3	2007-09-30	-17.2%
Q4	2007-12-31	100.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name

Q4 2007YOY CHG

Revenue

$4.37K

+86.6%

Gross Profit

$678.00

-58.7%

Gross Margin

15.52%

N/A

Market Cap

$200.00

N/A

Market Cap/Employee

$200.00

N/A

Employees

N/A

Net Income

-$1.17M

+37.4%

EBITDA

-$1.03M

+40.0%

Quarterly Fundamentals

Name

Q4 2007YOY CHG

Total Cash

$3.93K

-90.0%

Total Debt

$4.12M

-23.2%

Accounts Receivable

$1.87K

+164.0%

Inventory

$10.30K

-84.5%

Long Term Debt

$0.00

N/A

Short Term Debt

$4.12M

-23.2%

Return on Assets

-91.08%

N/A

Return on Invested Capital

10.36%

N/A

Free Cash Flow

-$110.32K

+83.6%

Operating Cash Flow

-$110.32K

+83.5%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

ONBIONE Bio Corp.

ONBIONE Bio Corp.$0.00+0.00%

ISOLFIsodiol International Inc.

ISOLFIsodiol International Inc.$0.00+0.00%

OWCPOWC Pharmaceutical Research Corp.

OWCPOWC Pharmaceutical Research Corp.$0.00+0.00%

RBIIRising Biosciences, Inc.

RBIIRising Biosciences, Inc.$0.00+0.00%

LADXLadRx Corporation

LADXLadRx Corporation$0.01-89.72%

MRPIMera Pharmaceuticals, Inc.

MRPIMera Pharmaceuticals, Inc.$0.00+0.00%

MLPHMolecular Pharmacology (USA), Ltd.

MLPHMolecular Pharmacology (USA), Ltd.$0.03+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

KHCKraft Heinz

KHCKraft Heinz$24.60+0.01%

ACVAACV Auctions

ACVAACV Auctions$10.41+0.44%

TNONTenon Medical

TNONTenon Medical$5.93+0.12%

ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF

ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF$19.16+0.03%

SMRNuScale Power

SMRNuScale Power$8.61-0.16%

NVDANvidia

NVDANvidia$218.29-0.00%

INTCIntel

INTCIntel$102.94+0.03%

Questions About NNBP

What is the current price of Nanobac Pharmaceuticals?

Nanobac Pharmaceuticals is trading at $0.00 per share.

What is the 52-week range for Nanobac Pharmaceuticals?

Over the past 52 weeks, Nanobac Pharmaceuticals has traded between $0.00 and $0.00.

How much debt does Nanobac Pharmaceuticals have?

Nanobac Pharmaceuticals total debt is unavailable.

How much cash does Nanobac Pharmaceuticals have on hand?

Nanobac Pharmaceuticals does not have cash on hand data available.

What is Nanobac Pharmaceuticals’s dividend yield?

Nanobac Pharmaceuticals does not currently have a dividend yield.

Nanobac Pharmaceuticals(OTC) NNBP

Nanobac Pharmaceuticals Financials at a Glance

NNBP News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Nanobac Pharmaceuticals

NNBP Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Nanobac Pharmaceuticals Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About NNBP

What is the current price of Nanobac Pharmaceuticals?

What is the 52-week range for Nanobac Pharmaceuticals?

How much debt does Nanobac Pharmaceuticals have?

How much cash does Nanobac Pharmaceuticals have on hand?

What is Nanobac Pharmaceuticals’s dividend yield?

Premium Investing Services